Careers  |  Sign In  |  Register  |   Twitter

Under-the-Tongue Droplets Effective for Treament of Allergy and Asthma

While up to 40% of the US population is affected by allergic rhinitis, sublingual immunotherapy is not approved by the FDA. A new study in The Journal of the American Medical Association reviews “the effectiveness and safety of aqueous sublingual immunotherapy for allergic rhinoconjunctivitis and asthma.” The results demonstrated strong evidence that sublingual immunotherapy improves asthma symptoms as 8 of 13 studies reported greater than 40% improvement vs the comparator, and it decreases rhinitis or rhinoconjunctivitis symptoms, with 9 of 36 studies demonstrating greater than 40% improvement vs the comparator.”

Read it in JAMA.